A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05795595 |
Recruitment Status :
Recruiting
First Posted : April 3, 2023
Last Update Posted : April 2, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Clear Cell Renal Cell Carcinoma Cervical Carcinoma Esophageal Carcinoma Pancreatic Adenocarcinoma Malignant Pleural Mesothelioma | Biological: CTX131 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 250 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors |
Actual Study Start Date : | March 13, 2023 |
Estimated Primary Completion Date : | April 2030 |
Estimated Study Completion Date : | May 2030 |
Arm | Intervention/treatment |
---|---|
Experimental: CTX131
Administered by IV infusion following lymphodepleting chemotherapy.
|
Biological: CTX131
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components) |
- Phase 1 (Dose Escalation): Incidence of adverse events [ Time Frame: From CTX131 infusion up to 28 days post-infusion ]Defined as dose-limiting toxicities
- Phase 2 (Cohort Expansion): Objective response rate (ORR) [ Time Frame: From CTX131 infusion up to 60 months post-infusion ]ORR based on Independent Review Committee (IRC) assessment, defined as the proportion of subjects who have achieved a best overall response of CR or PR according to appropriate response evaluation criteria for each disease histology
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Age ≥18 years.
- Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, endometrial carcinoma, and malignant pleural mesothelioma.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Adequate renal, liver, cardiac and pulmonary organ function.
- Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion.
Key Exclusion Criteria:
- Prior treatment with anti-CD70 targeting agents
- History of certain central nervous system (CNS), cardiac or pulmonary conditions.
- Presence of uncontrolled bacterial, viral, or fungal infection.
- Active HIV, hepatitis B virus or hepatitis C virus infection.
- Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
- Women who are pregnant or breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05795595
Contact: Central Trials | +1 (877) 214-4634 | MedicalAffairs@crisprtx.com |
United States, California | |
Research Site 3 | Recruiting |
Duarte, California, United States, 91010 | |
United States, Illinois | |
Research Site 7 | Recruiting |
Chicago, Illinois, United States, 60637 | |
United States, Massachusetts | |
Research Site 6 | Recruiting |
Boston, Massachusetts, United States, 02215 | |
United States, Missouri | |
Research Site 2 | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
United States, North Carolina | |
Research Site 4 | Recruiting |
Durham, North Carolina, United States, 27710 | |
United States, Tennessee | |
Research Site 1 | Recruiting |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
Research Site 5 | Recruiting |
Houston, Texas, United States, 77030 |
Study Director: | Alissa Keegan, MD, PhD | CRISPR Therapeutics |
Responsible Party: | CRISPR Therapeutics AG |
ClinicalTrials.gov Identifier: | NCT05795595 |
Other Study ID Numbers: |
CRSP-ONC-005 |
First Posted: | April 3, 2023 Key Record Dates |
Last Update Posted: | April 2, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
CAR-T Allogeneic Carcinoma |
Carcinoma Carcinoma, Renal Cell Mesothelioma Mesothelioma, Malignant Esophageal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases Adenoma Neoplasms, Mesothelial Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Pleural Neoplasms Lung Diseases Respiratory Tract Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Head and Neck Neoplasms |